Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA7 | P43166 | 2/20 | 0.35 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MMP14 | P50281 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15067956 | 1.00 | MAPT (0.44) | MAPTALDH1A1CA1CA2CA7 | |
| SCHEMBL31395611 | 0.94 | MAPT (0.49) | MAPTALDH1A1CA1CA2CA7 | |
| SCHEMBL30073354 | 0.94 | MAPT (0.49) | MAPTALDH1A1CA1CA2CA7 | |
| SCHEMBL15067601 | 0.94 | MAPT (0.49) | MAPTALDH1A1CA1CA2CA7 | |
| SCHEMBL12033232 | 0.94 | MAPT (0.49) | MAPTALDH1A1CA1CA2CA7 | |
| SCHEMBL789642 | 0.83 | GRIN2D (0.38) | MAPTALDH1A1CA1CA2CA7 | |
| SCHEMBL13593456 | 0.83 | MAPT (0.50) | MAPTALDH1A1CA1CA2CA7 | |
| SCHEMBL24365089 | 0.82 | ALDH1A1 (0.38) | MAPTALDH1A1CA1CA2CA7 | |
| SCHEMBL12528073 | 0.80 | MAPT (0.50) | MAPTALDH1A1CA1CA2CA7 | |
| SCHEMBL13591723 | 0.80 | MAPT (0.37) | MAPTALDH1A1CA1CA2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3539962-A1 | TETRACYCLIC BROMODOMAIN INHIBITORS | AbbVie Inc. (US) | 2019-09-18 | — | — | EP | disclosed |
| US-20190084981-A1 | Bromodomain Inhibitors | ABBVIE INC (US) | 2019-03-21 | — | — | US | disclosed |
| EP-3013827-A1 | BROMODOMAIN INHIBITORS | AbbVie Inc. (US) | 2016-05-04 | — | — | EP | disclosed |
| WO-2014206345-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC. (US) | 2014-12-31 | — | — | WO | disclosed |
| EP-2797918-A1 | BROMODOMAIN INHIBITORS | AbbVie Inc. (US) | 2014-11-05 | — | — | EP | disclosed |
| WO-2013097601-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC. (US) | 2013-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190084981-A1 | Bromodomain Inhibitors | BRD4, BRD1, BRD3 | MAPT 2884/4885ALDH1A1 2033/4885CA1 1495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.